Wockhardt Recalls Tamsulosin Hydrochloride Capsules Due to CGMP Deviations
Wockhardt USA Inc. is recalling Tamsulosin Hydrochloride Capsules because the firm did not adequately investigate customer complaints, a Current Good Manufacturing Practice (CGMP) deviation.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences. The specific deviation is a procedural failure (inadequate complaint investigation) rather than a confirmed contamination or defect causing injury, fitting the Moderate severity criteria for low-risk or procedural issues.
Plain-English summary
Wockhardt USA Inc. is recalling Tamsulosin Hydrochloride Capsules, USP, 0.4 mg, packaged in 100-count and 500-count bottles. The product is manufactured by Wockhardt Limited in Mumbai, India, and distributed by Wockhardt USA LLC in Parsippany, New Jersey. The recall covers 407,958 bottles distributed nationwide, including Puerto Rico.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm did not adequately investigate customer complaints. This procedural failure raises concerns about the quality control processes used to ensure the safety and efficacy of the medication.
Consumers who have purchased these specific lots of Tamsulosin Hydrochloride Capsules should stop using the product and contact their healthcare provider or pharmacist for guidance. The affected lots have expiration dates ranging from April 30, 2015, to September 30, 2015.
The recalled product
- Product
- Tamsulosin Hydrochloride Capsules, USP*, 0.4 mg Capsules, Packaged in A) 100 Count Bottles (NDC: 64679-516-02) and B) 500 Count Bottles (NDC: 64679-516-03), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 407,958
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- A) Lot #: LN10896
- Expiry: 4/30/2015
- Lot #: LN10901
- Lot #:LN10902
- Lot #: LN10903
- Lot #: LN11020
- Expiry: 5/31/2015
- Lot #: LN11021
- Lot #: LN11055
- Lot #: LN11056
- Lot #: LN11149
- Lot #: LN11150
- Lot #: LN11267
- Expiry: 6/30/2015
- Lot #: LN11357
- Expiry: 7/31/2015
- Lot #: LN11387
- Expiry: 8/31/2015
- Lot #: LN11421
- Expiry: 9/30/2015. B) Lot #: LN10808
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19